Jagsonpal Pharmaceuticals Q2 FY27 Revenue Climbs 29% to ₹964 Crore
By United One News · AI-generated summary of 5 outlets' reporting
Published · Updated
AI-generated summary of the coverage listed below:
Jagsonpal Pharmaceuticals reported a 29% rise in consolidated revenue to ₹964 crore for Q2 FY27, ending 30 September 2026.
- Revenue increased 29% year‑on‑year to ₹964 crore.
- Standalone operations revenue grew 9.3% to ₹814 crore.
- Standalone EBITDA reached ₹185 crore.
Covered by 5 outlets across the spectrum: 20% left, 60% center, 0% right.
How each side framed it
Left-leaning: CENTER: Focus on revenue growth, standalone performance, and EBITDA figures. (AI-generated summary of how this side framed it)
Business News | Thyrocare Technologies Limited Reports Revenue of INR 270.8 Cr in Q2 FY27, with a Growth of 25.1% YoY
Jagsonpal Pharmaceuticals’ Q2 FY27 Consolidated Revenue Rises 29% To ₹964 Crore
Timeline
First to report: Free Press Journal (); 5 articles from 5 outlets so far.
Who is covering this story
- Left-leaning (1): LatestLY
- Center (3): Free Press Journal, indianpharmapost, The Hindu BusinessLine
- Not yet rated (1): Entrackr
Sources
- Jagsonpal Pharmaceuticals’ Q2 FY27 Consolidated Revenue Rises 29% To ₹964 Crore — Free Press Journal (center) ·
- Business News | Thyrocare Technologies Limited Reports Revenue of INR 270.8 Cr in Q2 FY27, with a Growth of 25.1% YoY — LatestLY (left-leaning) ·
- Sanofi Consumer Healthcare India’s Q3 revenue rises 12% to Rs 263 Cr — indianpharmapost (center, AI-estimated) ·
- Smartworks posts Rs 591 Cr revenue and Rs 26 Cr profit in Q2 FY27 — Entrackr (not yet rated, AI-estimated) ·
- Reliance Consumer Products revenue jumps 60% to ₹8,266 crore on Campa, Independence growth — The Hindu BusinessLine (center) ·